Latest Kaiser Health News Stories
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
A retired California judge came up with the idea of donating his kidney to a stranger now to maximize his grandson’s prospects for such a donation later. The idea caught on.
Not only are health prices hidden, industry players are contractually obligated to keep them secret. That’s why answering a simple question — how much does it cost to have a baby in Mountain View, Calif.? — became a journalistic quest.
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
The Senate health committee is putting aside partisan bickering this month to seek a legislative remedy to a possible spike in Obamacare premiums this fall.
To strengthen your core knowledge of health care policy, it helps to be a regular reader of Kaiser Health News. Here’s a pop quiz to gauge what you have learned.
Gobbling up doctors’ independent practices is lucrative for hospital systems — but not necessarily a good deal for the physicians or consumers, critics say. Northern California is a case in point.
This immunization may mark a shift among some vaccine makers to higher-priced, “niche” preventives that protect against very specific and sometimes rare illnesses.
State leaders tell senators that federal dollars are needed this fall to keep insurers participating in Obamacare next year and prevent big hikes in premiums.
Hospice care often prompts fear and misunderstanding, but the services provided can lead to less pain and trauma at the end of life.
The fate of the Affordable Care Act’s individual insurance marketplaces remains in play as state insurance commissioners take a central role in the debate.
Most acquisitions by hospitals of physician practices are too small to trigger antitrust attention, study says. But a buying spree of “onesies and twosies” doctor practices has driven competition down and prices up.
No longer able to get exemptions for personal beliefs in California, parents opposed to inoculations seem to be obtaining medical exemptions for their children, according to a new study.
Innate Immunotherapeutics, the Australian biotech firm whose largest shareholder is Buffalo, N.Y.-area congressman Chris Collins, said it expects to close after its multiple sclerosis drug failed in trials.
After a Kaiser Health News report on an offshore herpes vaccine trial that skirted FDA regulations, St. Kitts and Nevis officials claim they had no knowledge of the testing. An investigation is underway.
The USA’s first approved gene therapy — to be used to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment.
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
Painkillers were never designed to be used over the long term, says the head of the Mayo Clinic’s pain rehabilitation center. Instead, patients should try other approaches, including relaxation therapies. But getting insurers to cover them might take coaxing.
Prominent businessmen and an American university supported offshore testing of an experimental vaccine.
State lawmakers in California have an answer: legislation that would require your new insurer to keep paying for your current doctors even if they’re not in the network.